These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 37980911)

  • 21. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.
    Guglielmetti L; Ardizzoni E; Atger M; Baudin E; Berikova E; Bonnet M; Chang E; Cloez S; Coit JM; Cox V; de Jong BC; Delifer C; Do JM; Tozzi DDS; Ducher V; Ferlazzo G; Gouillou M; Khan A; Khan U; Lachenal N; LaHood AN; Lecca L; Mazmanian M; McIlleron H; Moschioni M; O'Brien K; Okunbor O; Oyewusi L; Panda S; Patil SB; Phillips PPJ; Pichon L; Rupasinghe P; Rich ML; Saluhuddin N; Seung KJ; Tamirat M; Trippa L; Cellamare M; Velásquez GE; Wasserman S; Zimetbaum PJ; Varaine F; Mitnick CD
    Trials; 2021 Sep; 22(1):651. PubMed ID: 34563240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial.
    De Castro N; Marcy O; Chazallon C; Messou E; Eholié S; N'takpe JB; Bhatt N; Khosa C; Timana Massango I; Laureillard D; Chau GD; Domergue A; Veloso V; Escada R; Wagner Cardoso S; Delaugerre C; Anglaret X; Molina JM; Grinsztejn B;
    Lancet Infect Dis; 2021 Jun; 21(6):813-822. PubMed ID: 33667406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study.
    Korotych O; Achar J; Gurbanova E; Hovhannesyan A; Lomtadze N; Ciobanu A; Skrahina A; Dravniece G; Kuksa L; Rich M; Khachatryan N; Germanovych M; Kadyrov A; Terleieva I; Akhundova I; Adenov M; Durdyeva M; Kiria N; Parpieva N; Yatskevich N; Jumayev R; Nurov R; Diktanas S; Vilc V; Migliori GB; Yedilbayev A
    Lancet Infect Dis; 2024 Oct; 24(10):1151-1161. PubMed ID: 38880112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pretomanid for tuberculosis: a systematic review.
    Gils T; Lynen L; de Jong BC; Van Deun A; Decroo T
    Clin Microbiol Infect; 2022 Jan; 28(1):31-42. PubMed ID: 34400340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
    Conradie F; Bagdasaryan TR; Borisov S; Howell P; Mikiashvili L; Ngubane N; Samoilova A; Skornykova S; Tudor E; Variava E; Yablonskiy P; Everitt D; Wills GH; Sun E; Olugbosi M; Egizi E; Li M; Holsta A; Timm J; Bateson A; Crook AM; Fabiane SM; Hunt R; McHugh TD; Tweed CD; Foraida S; Mendel CM; Spigelman M;
    N Engl J Med; 2022 Sep; 387(9):810-823. PubMed ID: 36053506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A pragmatic randomized controlled trial to evaluate the efficacy and safety of an oral short-course regimen including bedaquiline for the treatment of patients with multidrug-resistant tuberculosis in China: study protocol for PROSPECT.
    Gao J; Gao M; Du J; Pang Y; Mao G; Lounis N; Bakare N; Jiang Y; Zhan Y; Liu Y; Li L;
    Trials; 2024 Apr; 25(1):227. PubMed ID: 38561815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study).
    Esmail A; Oelofse S; Lombard C; Perumal R; Mbuthini L; Goolam Mahomed A; Variava E; Black J; Oluboyo P; Gwentshu N; Ngam E; Ackerman T; Marais L; Mottay L; Meier S; Pooran A; Tomasicchio M; Te Riele J; Derendinger B; Ndjeka N; Maartens G; Warren R; Martinson N; Dheda K
    Am J Respir Crit Care Med; 2022 May; 205(10):1214-1227. PubMed ID: 35175905
    [No Abstract]   [Full Text] [Related]  

  • 29. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis.
    Grace AG; Mittal A; Jain S; Tripathy JP; Satyanarayana S; Tharyan P; Kirubakaran R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012918. PubMed ID: 31828771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of MDR, pre-XDR, XDR and rifampicin resistant tuberculosis or in case of intolerance to at least rifampicin in Austria, Germany and Switzerland - Amendment dated 19.09.2023 to the Sk2-Guideline: Tuberculosis in adulthood of the German Central Committee against Tuberculosis (DZK) on behalf of the German Respiratory Society (DGP)].
    Otto-Knapp R; Bauer T; Brinkmann F; Feiterna-Sperling C; Friesen I; Geerdes-Fenge H; Hartmann P; Häcker B; Hauer B; Haas W; Heyckendorf J; Kuhns M; Lange C; Maurer FP; Nienhaus A; Priwitzer M; Richter E; Salzer HJF; Schoch O; Schönfeld N; Schaberg T
    Pneumologie; 2024 Jan; 78(1):35-46. PubMed ID: 37931778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
    Borchmann P; Plütschow A; Kobe C; Greil R; Meissner J; Topp MS; Ostermann H; Dierlamm J; Mohm J; Thiemer J; Sökler M; Kerkhoff A; Ahlborn M; Halbsguth TV; Martin S; Keller U; Balabanov S; Pabst T; Vogelhuber M; Hüttmann A; Wilhelm M; Zijlstra JM; Moccia A; Kuhnert G; Bröckelmann PJ; von Tresckow B; Fuchs M; Klimm B; Rosenwald A; Eich H; Baues C; Marnitz S; Hallek M; Diehl V; Dietlein M; Engert A
    Lancet Oncol; 2021 Feb; 22(2):223-234. PubMed ID: 33539742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial.
    Lee JK; Lee JY; Kim DK; Yoon HI; Jeong I; Heo EY; Park YS; Jo YS; Lee JH; Park SS; Park JS; Kim J; Lee SM; Joh JS; Lee CH; Lee J; Choi SM; Park JH; Lee SH; Cho YJ; Lee YJ; Kim SJ; Kwak N; Hwang YR; Kim H; Ki J; Lim JN; Choi HS; Lee M; Song T; Kim HS; Han J; Ahn H; Hahn S; Yim JJ
    Lancet Infect Dis; 2019 Jan; 19(1):46-55. PubMed ID: 30477961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Savings from the introduction of BPaL and BPaLM regimens at the country level.
    Auer C; Gupta A; Malbacius C; Ghafoor A; Kock Y; Medvedieva O; Hanlon P; Steinmann P; Juneja S
    IJTLD Open; 2024 Jul; 1(7):314-319. PubMed ID: 39035434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral linezolid compared with benzathine penicillin G for treatment of early syphilis in adults (Trep-AB Study) in Spain: a prospective, open-label, non-inferiority, randomised controlled trial.
    Ubals M; Nadal-Baron P; Arando M; Rivero Á; Mendoza A; Descalzo Jorro V; Ouchi D; Pérez-Mañá C; Álvarez M; Alemany A; Hoyos-Mallecot Y; Nunley E; Lieberman NAP; Greninger AL; Galván-Casas C; Suñer C; G-Beiras C; Paredes R; Rodríguez-Gascón A; Canut A; García-Patos V; Farré M; Marks M; Giacani L; Vall-Mayans M; Mitjà O
    Lancet Infect Dis; 2024 Apr; 24(4):404-416. PubMed ID: 38211601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial.
    Phillips RO; Robert J; Abass KM; Thompson W; Sarfo FS; Wilson T; Sarpong G; Gateau T; Chauty A; Omollo R; Ochieng Otieno M; Egondi TW; Ampadu EO; Agossadou D; Marion E; Ganlonon L; Wansbrough-Jones M; Grosset J; Macdonald JM; Treadwell T; Saunderson P; Paintsil A; Lehman L; Frimpong M; Sarpong NF; Saizonou R; Tiendrebeogo A; Ohene SA; Stienstra Y; Asiedu KB; van der Werf TS;
    Lancet; 2020 Apr; 395(10232):1259-1267. PubMed ID: 32171422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment Strategy for Rifampin-Susceptible Tuberculosis.
    Paton NI; Cousins C; Suresh C; Burhan E; Chew KL; Dalay VB; Lu Q; Kusmiati T; Balanag VM; Lee SL; Ruslami R; Pokharkar Y; Djaharuddin I; Sugiri JJR; Veto RS; Sekaggya-Wiltshire C; Avihingsanon A; Sarin R; Papineni P; Nunn AJ; Crook AM;
    N Engl J Med; 2023 Mar; 388(10):873-887. PubMed ID: 36808186
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Person-centred experiential therapy versus cognitive behavioural therapy delivered in the English Improving Access to Psychological Therapies service for the treatment of moderate or severe depression (PRaCTICED): a pragmatic, randomised, non-inferiority trial.
    Barkham M; Saxon D; Hardy GE; Bradburn M; Galloway D; Wickramasekera N; Keetharuth AD; Bower P; King M; Elliott R; Gabriel L; Kellett S; Shaw S; Wilkinson T; Connell J; Harrison P; Ardern K; Bishop-Edwards L; Ashley K; Ohlsen S; Pilling S; Waller G; Brazier JE
    Lancet Psychiatry; 2021 Jun; 8(6):487-499. PubMed ID: 34000240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.
    von Groote-Bidlingmaier F; Patientia R; Sanchez E; Balanag V; Ticona E; Segura P; Cadena E; Yu C; Cirule A; Lizarbe V; Davidaviciene E; Domente L; Variava E; Caoili J; Danilovits M; Bielskiene V; Staples S; Hittel N; Petersen C; Wells C; Hafkin J; Geiter LJ; Gupta R
    Lancet Respir Med; 2019 Mar; 7(3):249-259. PubMed ID: 30630778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines.
    Gomez GB; Siapka M; Conradie F; Ndjeka N; Garfin AMC; Lomtadze N; Avaliani Z; Kiria N; Malhotra S; Cook-Scalise S; Juneja S; Everitt D; Spigelman M; Vassall A
    BMJ Open; 2021 Dec; 11(12):e051521. PubMed ID: 34862287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.